205 related articles for article (PubMed ID: 29390380)
1. Significant efficacy and well safety of apatinib combined with radiotherapy in NSCLC: Case report.
Zhao C; Zhang Q; Qiao W
Medicine (Baltimore); 2017 Dec; 96(50):e9276. PubMed ID: 29390380
[TBL] [Abstract][Full Text] [Related]
2. The Use of Apatinib in Treating Nonsmall-Cell Lung Cancer: Case Report and Review of Literature.
Ding L; Li QJ; You KY; Jiang ZM; Yao HR
Medicine (Baltimore); 2016 May; 95(20):e3598. PubMed ID: 27196461
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of apatinib combined with iodine-125 in chemotherapy-refractory advanced lung cancer: A case report.
Zhang Y; Yin S; Jia Y; Qin L
Medicine (Baltimore); 2020 Aug; 99(33):e21600. PubMed ID: 32872014
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of apatinib in patients with advanced nonsmall cell lung cancer that failed prior chemotherapy or EGFR-TKIs: A pooled analysis.
Ma JT; Sun J; Sun L; Zhang SL; Huang LT; Han CB
Medicine (Baltimore); 2018 Aug; 97(35):e12083. PubMed ID: 30170427
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment using apatinib with or without docetaxel in heavily pretreated advanced non-squamous non-small cell lung cancer: A case report and literature review.
Wu F; Zhang S; Gao G; Zhao J; Ren S; Zhou C
Cancer Biol Ther; 2018 Mar; 19(3):141-144. PubMed ID: 29261000
[TBL] [Abstract][Full Text] [Related]
6. Apatinib for advanced nonsmall-cell lung cancer: A retrospective case series analysis.
Yang C; Feng W; Wu D
J Cancer Res Ther; 2018 Jan; 14(1):159-162. PubMed ID: 29516980
[TBL] [Abstract][Full Text] [Related]
7. The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).
Zhang Z; Luo F; Zhang Y; Ma Y; Hong S; Yang Y; Fang W; Huang Y; Zhang L; Zhao H
Cancer Commun (Lond); 2019 Nov; 39(1):69. PubMed ID: 31699150
[TBL] [Abstract][Full Text] [Related]
8. Apatinib monotherapy for advanced non-small cell lung cancer after the failure of chemotherapy or other targeted therapy.
Liu Z; Ou W; Li N; Wang SY
Thorac Cancer; 2018 Oct; 9(10):1285-1290. PubMed ID: 30126078
[TBL] [Abstract][Full Text] [Related]
9. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R
Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671
[TBL] [Abstract][Full Text] [Related]
10. Apatinib Monotherapy or Combination Therapy for Non-Small Cell Lung Cancer Patients With Brain Metastases.
Xu J; Liu X; Yang S; Shi Y
Oncol Res; 2020 Mar; 28(2):127-133. PubMed ID: 31610827
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of apatinib plus docetaxel as the second or above line treatment in advanced nonsquamous NSCLC: A multi center prospective study.
Jiang Q; Zhang NL; Ma DY; Tan BX; Hu X; Fang XD
Medicine (Baltimore); 2019 Jun; 98(26):e16065. PubMed ID: 31261514
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, safety and predictive indicators of apatinib after multilines treatment in advanced nonsquamous nonsmall cell lung cancer: Apatinib treatment in nonsquamous NSCLC.
Wu D; Liang L; Nie L; Nie J; Dai L; Hu W; Zhang J; Chen X; Han J; Ma X; Tian G; Han S; Long J; Wang Y; Zhang Z; Xin T; Fang J
Asia Pac J Clin Oncol; 2018 Dec; 14(6):446-452. PubMed ID: 29573236
[TBL] [Abstract][Full Text] [Related]
13. A Phase II Clinical Trial of Apatinib in Pretreated Advanced Non-squamous Non-small-cell Lung Cancer.
Wu F; Zhang S; Xiong A; Gao G; Li W; Cai W; Su C; Chen X; Zhou F; Zhao J; Ren S; Zhou C
Clin Lung Cancer; 2018 Nov; 19(6):e831-e842. PubMed ID: 30026059
[TBL] [Abstract][Full Text] [Related]
14. Low dose of apatinib in treating chemotherapy and EGFR-TKI refractory non-small cell lung cancer: A case report.
Liu J; Zheng Y; Xu N
Medicine (Baltimore); 2019 Feb; 98(5):e14328. PubMed ID: 30702616
[TBL] [Abstract][Full Text] [Related]
15. Continuous Low-Dose Apatinib Combined With WBRT Significantly Reduces Peritumoral Edema and Enhances the Efficacy of Symptomatic Multiple Brain Metastases in NSCLC.
Ren Y; Wang SB; Zhou L; Liu SQ; Du LY; Li T; Jiang MQ; Lei KJ; Tan BX; Jia YM
Technol Cancer Res Treat; 2021; 20():15330338211011968. PubMed ID: 33955301
[TBL] [Abstract][Full Text] [Related]
16. A phase I dose-reduction study of apatinib combined with pemetrexed and carboplatin in untreated EGFR and ALK negative stage IV non-squamous NSCLC.
Huang M; Gong Y; Zhu J; Qin Y; Peng F; Ren L; Ding Z; Liu Y; Cai C; Wang Y; Lu Y
Invest New Drugs; 2020 Apr; 38(2):478-484. PubMed ID: 31231786
[TBL] [Abstract][Full Text] [Related]
17. Apatinib is effective as third-line and more treatment of advanced metastatic non-small-cell lung cancer: A retrospective analysis in a real-world setting.
Leng J; Li DR; Huang LM; Ji XH; Wang DL
Medicine (Baltimore); 2019 Sep; 98(36):e16967. PubMed ID: 31490378
[TBL] [Abstract][Full Text] [Related]
18. Apatinib plus Chemotherapy as a Second-Line Treatment in Unresectable Non-Small Cell Lung Carcinoma: A Randomized, Controlled, Multicenter Clinical Trial.
Yu Z; Cai X; Xu Z; He Z; Lai J; Wang W; Zhang J; Kong W; Huang X; Chen Y; Shi Y; Shi X; Zhao Z; Ni M; Lin X; Chen S; Wu X; Chen W; Song Z; Huang C
Oncologist; 2020 Nov; 25(11):e1640-e1649. PubMed ID: 32533785
[TBL] [Abstract][Full Text] [Related]
19. A case report of apatinib in treating osteosarcoma with pulmonary metastases.
Zhou Y; Zhang W; Tang F; Luo Y; Min L; Zhang W; Shi R; Duan H; Tu C
Medicine (Baltimore); 2017 Apr; 96(15):e6578. PubMed ID: 28403086
[TBL] [Abstract][Full Text] [Related]
20. Long-term response with low-dose of apatinib combined with S-1 in pretreated patient with advanced squamous cell lung cancer: A case report.
Chen J; Wang J; Zou Y
Medicine (Baltimore); 2021 Feb; 100(8):e24390. PubMed ID: 33663051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
